Merck is a drugmaker whose biggest product is Keytruda, one of the world's top-selling cancer treatments.
Merck & Co., Inc. (MRK) is expected to report earnings on Thursday, October 29, 2026, before the open. Estimated release time 06:44 ET. Consensus EPS estimate is $2.09.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | Jun 2026 qtr | $-0.27 | $-0.13 | — | $16.61B |
| 2026-04-30 | Mar 2026 qtr | $-1.47 | $-1.28 | +12.9% | $16.29B |
| 2026-02-03 | Dec 2025 qtr | $2.01 | $2.04 | +1.5% | $16.40B |
| 2025-10-30 | Sep 2025 qtr | $2.36 | $2.58 | +9.3% | $17.18B |
| 2025-07-29 | Jun 2025 qtr | $2.03 | $2.13 | +4.9% | $15.80B |
| 2025-04-24 | Mar 2025 qtr | $2.13 | $2.22 | +4.2% | $15.62B |
| 2025-02-04 | Dec 2024 qtr | $1.85 | $1.72 | -7.0% | $15.62B |
| 2024-10-31 | Sep 2024 qtr | $1.50 | $1.57 | +4.7% | $16.66B |
MRK has beaten consensus EPS in 6 of its last 7 scored quarters.
MRK pays a quarterly dividend, currently yielding 2.36%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-09-15 | $0.85 | 2026-10-07 |
| 2026-06-15 | $0.85 | 2026-07-08 |
| 2026-03-16 | $0.85 | 2026-04-07 |
| 2025-12-15 | $0.85 | 2026-01-08 |
| 2025-09-15 | $0.81 | 2025-10-07 |
| 2025-06-16 | $0.81 | 2025-07-08 |